

## References

### I-9032

1. Qalsody™ (tofersen) injection for intrathecal use [package insert]. accessed May 4, 2023 [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2023/215887s0001bl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215887s0001bl.pdf)
2. Kiernan M. C., Vucic S., Cheah B. C., Turner M. R., Eisen A., Hardiman O., et al. (2011). Amyotrophic lateral sclerosis. *Lancet* 377 942–955. 10.1016/S0140-6736(10)61156-7.
3. Miller R.G., Jackson C.E., Kasarskis E.J., England J.D., ForsheW D., Johnston W., Kalra S., Katz J.S., Mitsumoto H., Rosenfeld J., et al. Practice parameter update: The care of the patient with amyotrophic lateral sclerosis: Multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): Report of the Quality Standards Subcommittee of the American of Neurology. *Neurology*. 2009;73:1227–1233.
4. Clinical Review Report: Edaravone (Radicava): (Mitsubishi Tanabe Pharma Corporation): Indication: For the treatment of amyotrophic lateral sclerosis [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Apr. <https://www.ncbi.nlm.nih.gov/books/NBK542359/>.
5. Oskarsson B., Gendron T., Staff N. Amyotrophic Lateral Sclerosis: An Update for 2018. *Mayo Clin Proc*. 2018;93(11):1617-1628.
6. Berdyński, M., Miszta, P., Safranow, K. *et al.* *SOD1* mutations associated with amyotrophic lateral sclerosis analysis of variant severity. *Sci Rep* 12;103 (2022). <https://doi.org/10.1038/s41598-021-03891-8>.
7. Miller T, Cudkowicz M, Shaw P, et al. Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. *N Engl J Med*. 2020;383(2):109-19. doi: 10.1056/NEJMoa2003715.
8. Miller TM, Cudkowicz ME, Genge A, et al. Trial of Antisense Oligonucleotide Tofersen for *SOD1* ALS. *N Engl J Med*. 2022;387(12):1099-1110. doi:10.1056/NEJMoa2204705.